Competing interests: DT received research funding from Sobi, Sumitomo, Cogent Biosciences and Gilead and honoraria from Sobi, Novartis, AbbVie, PharmaEssentia, Sierra Oncology, GSK and Cogent Biosciences. CDD received honoraria from Abbvie, AstraZeneca, BMS, Genentech, GenMab, GSK, Immunogen, Notable Labs, Rigel, Schrodinger, and Servier and grant support from LLS Scholar in Research Award. TMK received research funding from AbbVie and Genentech and honoraria from AbbVie. FR received research funding from AbbVie and BMS and honoraria from AbbVie and BMS. AM received research funding from BMS, Incyte and Novartis. AA received research funding from Novartis, BMS, Onconova, Medimmune, Ariad, GSK, Celgene, Eisai, ALX Oncology, H3B Biomedicine/Hemavant. MK has received honoraria from Protagonist, Silence Therapeutics, Morphosys, Incyte, AbbVie and Kura. JF received research funding from Oryzon Genomics, Taiho Oncology, and Syros. RK received research funding from BMS and honoraria from Abbvie, BMS, DSI, Geron, Janssen, Jazz, PharmaEssentia, Rigel, Servio, Sobi, and Sumitomo. JM received research funding from Incyte, BMS, Novartis, Abbvie, Geron, Kartos, Karyopharm, Sobi and PharmaEssentia and honoraria from Incyte, BMS, Abbvie, Kartos, Geron, GSK, Roche, Merck, Pfizer, PharmaEssentia, MorphoSys, Novartis, Galecto, Sobi, Sumitomo, and Karyopharm. EP received research funding from Incyte, BMS, and Blueprint and honoraria from BMS, GSK, Sobi, Blueprint, Taiho, PharmaEssentia. DAS received research funding from Aprea and Jazz and honoraria from AbbVie, Aprea, Agios, Celyad, Froghorn, Gilead,Incyte, Intellisphere LLC, Kite, Megenta, Novartis, AvenCell, Astellas, BlueBird Bio, BMS, Dark Blue Therapeutics, Intellia, Jasper Therapeutics, Kite, Magenta Therapeutics, NKARTA, Novartis, Orbital Therapeutics, Rigel Pharmaceuticals, Shattuck Labs, Servier, Syndax, and Syros. MMP received research funding from Stemline, Kura Oncology, Solu Therapeutics, Epigenetix and Polaris Pharmaceuticals. GMB received research funding from IFM Therapeutics, Takeda Oncology, Solu Theraputics. The remaining of the authors have no potential competing interests to disclose. Ethics approval and consent to participate: This study received approval by the Institutional Review Boards from all participating institutions and research was conducted in accordance with the Declaration of Helsinki. Given the retrospective nature of this analysis, informed consent was not required by local regulatory authorities.